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Nicholls et al. (1), based on data from the PERISCOPE (Piogli-
tazone Effect on Regression of Intravascular Sonographic Coro-
nary Obstruction Prospective Evaluation) study, reported that the
favorable effects of pioglitazone on the triglyceride-to-high-density
lipoprotein (trig/HDL) ratio correlated with delayed atheroma
progression in diabetic patients. Nowhere in the paper do the
authors recognize the association of the trig/HDL ratio with
insulin resistance and the other manifestations of the metabolic
syndrome. The trig/HDL ratio is a simple way to identify
insulin-resistant individuals at increased risk of cardiovascular
disease and has also been shown to predict the low-density
lipoprotein particle size in Asian Indians (2–4).
Therefore, it is highly likely that the effect of pioglitazone in
ecelerating the formation of coronary artery atheroma was at least
n part due to pioglitazone’s ability to lower insulin resistance,which in turn reduces inflammation and post-prandial glucose—2
other potent and independent risk factors for atherosclerotic
progression and adverse cardiovascular events (5,6).
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